## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.1% in lower entry zone (4.0-10.0%), top quartile (88th pct) cross-sectional ranking. Short-term MRS_5 (0.3%) confirms momentum alignment. Outperforming sector by 4.5%. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($26.07)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 12-Month Share Price Rally**
- Source: Simply Wall Street | 20251221T210959 | Somewhat-Bullish | Relevance: 100%
- ACADIA Pharmaceuticals (ACAD) has seen significant growth in its share price over the past year, up 61%, and is currently trading just below consensus price targets. Despite this rally, a detailed long-term cash flow analysis suggests the stock might be modestly undervalued, with a narrative fair value of $29.32 against a current price of $27.16. The valuation hinges on assumptions of durable double-digit growth and steady margins, and investors should consider potential risks like NUPLAZIDâ€™s concentration risk or setbacks in late-stage trials.

**2. Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com**
- Source: Investing.com Nigeria | 20251223T030847 | Bullish | Relevance: 100%
- Acadia Pharmaceuticals stock aggressively rose to a 52-week high of $27.73, marking a 61% increase over the past year and reflecting strong investor confidence. The company's financial health is rated "GREAT" with a robust current ratio of 3.02, and it appears undervalued despite its strong performance. Recent FDA approval for DAYBUE STIX and varied analyst price target adjustments further contribute to its positive outlook.

**3. Acadia Pharmaceuticals stock reaches 52-week high at $27.73 By Investing.com**
- Source: Investing.com Canada | 20251222T160959 | Bullish | Relevance: 100%
- Acadia Pharmaceuticals stock has reached a 52-week high of $27.73, reflecting a 61% increase over the past year and strong investor confidence. The company maintains a "GREAT" financial health score and its stock appears undervalued at its current price. Recent FDA approval for DAYBUE STIX and varied analyst price target adjustments further contribute to a positive outlook for the biopharmaceutical firm.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | HC Wainwright & | $37 | $32 | +16% |
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | HC Wainwright & | main | Buy |
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (3 raises, avg +14%). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.67 |
| 52W Range | $13.40 - $28.34 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 34.6 |
| Current P/E | 34.2 |
| YoY Growth | -1.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 7.1% to 4.1% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 0.3% confirms short-term momentum alignment. AM_20 at 5.2% shows strong absolute momentum above own 20MA. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.11% (CS: 88) | Strong |
| RSI_14 | 67.6 | Neutral |
| MACD Histogram | 0.00 | Bearish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 1.156x | Above |
| vs SMA200 | 1.290x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $27.83
- **Stop Loss:** $26.07 (6.3% risk)
- **Target:** $30.47 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 681
- **Position Value:** $18,952.23
- **Portfolio %:** 18.95%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*